Anxiety & Stress — Peptide Research Overview

Relevant Compounds

• Selank — Tuftsin analog with anxiolytic, adaptogenic, and mild nootropic properties. Registered in Russia for anxiety disorders. No known dependence potential.
• Semax — ACTH(4-7)PGP analog; reduces stress-related cortisol responses, increases BDNF, and improves cognitive performance under stress conditions.

What the Research Shows

Selank

[Human Trial — Russia] Selank is registered in Russia as a drug for generalized anxiety disorder and asthenic conditions. In randomized comparative trials, intranasal Selank showed efficacy comparable to oxazolam (a benzodiazepine) for anxiety reduction with no sedation, no withdrawal effects, and no cognitive impairment. Mechanistically, it stabilizes enkephalin degradation (thereby prolonging endogenous opioid/anxiolytic signaling), modulates GABA-A receptor expression, and increases serotonin turnover. It also increases BDNF, contributing to its adaptogenic and mild cognitive-enhancing properties.

The primary clinical trial enrolled patients with generalized anxiety disorder and compared Selank 0.15% intranasal drops (2-3 drops per nostril, 2-3 times daily) with oxazolam 10 mg three times daily over 14 days. Both treatments significantly reduced anxiety scores on the Hamilton Anxiety Rating Scale (HAM-A), with no statistical difference in efficacy. However, Selank produced no sedation, no psychomotor impairment, and no rebound anxiety upon discontinuation—all common issues with benzodiazepines.

Additional studies have demonstrated Selank's effects on immune function, with normalization of IL-6 and other cytokine profiles in patients with anxiety disorders. This immunomodulatory effect suggests potential benefits for stress-related immune suppression. Gene expression studies show that Selank influences the expression of genes related to neurotransmitter synthesis, oxidative stress response, and neuroplasticity. The compound's safety profile includes no observed hepatotoxicity, nephrotoxicity, or endocrine disruption in clinical use, though long-term data beyond several months is limited.

Semax

[Human Trial — Russia / Preliminary] While Semax is primarily studied for cognitive enhancement and neuroprotection, secondary analyses and smaller clinical observations document stress-reducing effects. It reduces HPA axis hyperreactivity, normalizes cortisol responses, and has been noted to reduce performance anxiety in clinical populations. The combination of Selank (anxiolysis) and Semax (cognitive enhancement) is commonly described in research use for stress-heavy work demands.

Semax acts through multiple mechanisms including upregulation of brain-derived neurotrophic factor (BDNF), modulation of the melanocortin system, and influence on dopamine and serotonin metabolism. In stress paradigms, Semax prevents the excessive cortisol elevation typically seen with acute stressors, suggesting a protective effect on HPA axis function. This may be particularly relevant for chronic stress conditions where HPA dysregulation is common.

Clinical applications in Russia include treatment of patients recovering from stroke, traumatic brain injury, and optic nerve pathology, where both neuroprotection and stress reduction are relevant. Anecdotal reports from research contexts describe improved focus, reduced performance anxiety during exams or presentations, and better stress tolerance during demanding work periods. Typical dosing involves intranasal administration of 0.1% solution, 2-3 drops per nostril, 1-3 times daily for periods ranging from 10 days to several weeks.

How These Compounds Work

Selank's anxiolytic mechanism is multifaceted. By inhibiting enzymes that degrade enkephalins (endogenous opioid peptides), it prolongs the activity of these naturally calming neurotransmitters. This is distinct from exogenous opioid administration and does not activate mu-opioid receptors in a way that produces euphoria or dependence. Selank also upregulates GABA-A receptor expression, enhancing inhibitory neurotransmission without directly acting as a GABA agonist like benzodiazepines do.

The serotonergic effects of Selank involve increased serotonin turnover in specific brain regions associated with anxiety regulation, including the hippocampus and prefrontal cortex. Increases in BDNF contribute to neuroplasticity and may support long-term resilience to stress. The immunomodulatory effects, particularly normalization of inflammatory cytokines, address the bidirectional relationship between inflammation and anxiety.

Semax operates primarily through neurotrophic and neuroprotective pathways. By increasing BDNF expression, it enhances synaptic plasticity and neuronal survival. The melanocortin system modulation influences stress responses, mood regulation, and cognitive function. Semax's effects on the HPA axis appear to involve normalization of cortisol secretion patterns rather than simple suppression, allowing adaptive stress responses while preventing maladaptive hyperreactivity.

Who Is This For?

These peptides may be appropriate for individuals with generalized anxiety, performance anxiety, or chronic stress who have not responded adequately to first-line interventions or who wish to avoid the side effects of conventional medications. They may be particularly relevant for those who experience cognitive impairment from benzodiazepines or emotional blunting from SSRIs.

Ideal candidates are those with mild to moderate anxiety rather than severe, treatment-resistant conditions. Selank appears most suited for individuals with generalized anxiety and worry, while Semax may benefit those whose anxiety is related to performance demands or cognitive stress. Both compounds require intranasal administration, which some may find inconvenient compared to oral medications.

These interventions are not appropriate as sole treatment for severe anxiety disorders, particularly those with panic attacks, severe agoraphobia, or co-occurring substance use disorders. They are not registered or approved outside of Russia, meaning use elsewhere is off-label and experimental. Individuals should have realistic expectations about the quality and limitations of the available evidence, which primarily comes from Russian research institutions with limited independent Western replication.

Protocol Considerations

Selank is typically administered intranasally using 0.15% drops, 2-3 drops per nostril, 2-3 times daily. Treatment courses commonly run 14-28 days, though some protocols use longer durations or intermittent cycles (e.g., 2 weeks on, 1 week off). Effects are generally noticed within the first few days, unlike SSRIs which require weeks to reach efficacy. Some users report optimal effects with morning and midday dosing to support daytime anxiety management without interfering with sleep.

Semax intranasal administration typically uses 0.1% solution, 2-3 drops per nostril, 1-2 times daily. Courses range from 10-30 days. Given its cognitive-enhancing properties, it is often dosed in the morning or before cognitively demanding tasks. Combining Selank and Semax is described in research contexts, with protocols using Selank for baseline anxiety reduction and Semax for cognitive performance under stress.

Neither compound appears to require gradual titration or tapering, unlike benzodiazepines or SSRIs. However, chronic use beyond a few months has limited safety data. Cycling approaches (using for defined periods rather than continuously) may be prudent until longer-term studies are available. Proper intranasal administration technique is important—spraying into the nostrils while breathing in gently, avoiding immediately blowing the nose or sniffing forcefully.

What to Track

Anxiety Symptoms: Subjective anxiety levels (0-10 scale), frequency and intensity of worry, physical symptoms (muscle tension, restlessness, fatigue), sleep quality, and specific anxiety triggers or situations.

Cognitive Function: Focus and concentration, memory, mental clarity, cognitive fatigue, and performance on demanding tasks. This is particularly relevant for Semax.

Mood and Affect: Overall mood, emotional range, anhedonia (loss of pleasure), irritability, and any emotional blunting or flattening.

Stress Response: Perceived stress levels, ability to handle stressors, recovery time after stressful events, and any changes in stress-coping strategies.

Physical Markers: Blood pressure and heart rate (anxiety often elevates these), sleep architecture if using sleep tracking, and any somatic symptoms like headaches or gastrointestinal issues.

Side Effects: Nasal irritation or discomfort, changes in sense of smell, headaches, dizziness, or any other unusual symptoms. Both compounds have favorable safety profiles in available trials, but individual responses vary.

Evidence Summary